Evaro raises USD $25m to scale embedded UK healthcare

Evaro has raised USD $25 million in a Series A funding round as it expands a regulated "healthcare-as-a-service" model for consumer brands and other partners in the UK.

The Norwich-based company said the round was led by AlbionVC, with participation from Simplyhealth Ventures, Exceptional Ventures, Cornerstone VC, and BBI. AlbionVC Partner Christoph Ruedig will join Evaro's board.

Evaro said its platform already serves more than 2 million patients. It aims to reach 10 million patients over the next three years.

Embedded healthcare

Evaro positions its service as infrastructure that external partners can embed into their own digital experiences. The company said its partners include period-tracking app Clue and sexual wellness retailer Lovehoney.

The company said it lets partners offer asynchronous consultations, remote diagnostics, prescribing, dispensing, and aftercare. It said integrations can complete in as little as two weeks.

Evaro said it holds Care Quality Commission and General Pharmaceutical Council licences and has NHS integration that enables GP record access. The company said it has seven active regulatory approvals.

Primary care pressure

The funding comes against a backdrop of continued strain in UK primary care access. Evaro cited data that 20.5 million people experienced month-long waits for a GP appointment in 2024, up 60% in seven years.

The company also pointed to evidence on remote-first models for common conditions. A 2023 BJGP Open study found that well-designed asynchronous consultations can resolve up to 66% of primary care cases without live appointments.

Evaro said it sees an opportunity for alternative routes into regulated care through brands and other partners that already have direct relationships with consumers.

Three markets

Evaro said it targets three customer segments. These include consumer brands that want to add prescription healthcare, healthcare providers that want to expand digital capacity for common conditions, and employers that offer health benefits.

It said the platform provides the regulated clinical and pharmacy components needed for those services. It also said the model creates additional revenue streams for partners.

Evaro said it has a 4.5 rating on Trustpilot.

"When a third of people are waiting over a week just to see their GP, it's time to think through alternative solutions that help people get the care they need while supporting NHS capacity. What we've built is infrastructure that allows our partners - brands people already trust - to deliver safe and regulated healthcare for common conditions without having to build a thing. We're making healthcare as accessible as online banking, and this funding lets us prove that model works at scale." said Dr. Thuria Wenbar, CEO and Co-Founder, Evaro.

Product roadmap

Evaro said it will use the new capital to expand across treatment areas. It listed women's health, men's health, and longevity medicine.

The company also said it plans to expand clinical work in diagnostics and aftercare. It said it will continue platform development, including an API-first approach for brand integrations.

Evaro was founded in 2018 by emergency physician Dr Thuria Wenbar and pharmacist researcher Dr Oskar Wenbar.

Investors framed the company's model as part of a wider trend of embedding regulated services into consumer products. "We've seen embedded finance transform banking, Evaro is now driving the embedded health revolution," said Christoph Ruedig, Partner at AlbionVC, who joins Evaro's board.

"Evaro has spent seven years building its infrastructure properly, with deep regulatory credentials. This now allows consumer brands to enter the healthcare space safely, unlocking massive latent demand while relieving pressure on the NHS. We are thrilled to back the team as they define this new category," said Ruedig.

Changing expectations

In addition to consumer brands, Evaro's model also targets healthcare organisations that want to add digital pathways for minor conditions and follow-on care. The company said its service includes prescribing and dispensing as well as aftercare, rather than limiting offerings to triage and consultations.

It also targets employers, where UK companies have expanded employee health benefits in response to pressures in public provision and rising demand for faster access.

Dr Oskar Wenbar described a shift in expectations for access and convenience. "Patients now expect the same convenience from healthcare that they get from banking or shopping-instant, mobile, on their terms. The technology exists to deliver this for minor conditions, but our system is still stuck requiring appointments, phone calls, physical visits - with no capacity for smart aftercare. We want to solve this, and scale the infrastructure that matches how people actually want to access care in 2026," said Dr. Oskar Wenbar, Chief Medical Officer and Co-Founder, Evaro.